Show simple item record

dc.contributor.authorLin, J. J.en
dc.contributor.authorDrilon, A. E.en
dc.contributor.authorCho, B. C.en
dc.contributor.authorFelip, E.en
dc.contributor.authorDe Langen, A.en
dc.contributor.authorYang, N.en
dc.contributor.authorKim, S. W.en
dc.contributor.authorLu, S.en
dc.contributor.authorKao, S. C. H.en
dc.contributor.authorVelcheti, V.en
dc.contributor.authorMoro Sibilot, D. L.en
dc.contributor.authorSolomon, B. J.en
dc.contributor.authorDziadziuszko, R.en
dc.contributor.authorKrebs, Matthew Gen
dc.contributor.authorCheema, P. K.en
dc.contributor.authorDooms, C. A.en
dc.contributor.authorStopatschinskaja, S.en
dc.contributor.authorTrone, D.en
dc.contributor.authorAdes, F.en
dc.contributor.authorCamidge, D. R.en
dc.date.accessioned2023-10-25T08:48:37Z
dc.date.available2023-10-25T08:48:37Z
dc.date.issued2023en
dc.identifier.citationLin JJ, Drilon AE, Cho BC, Felip E, De Langen A, Yang N, et al. Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003685.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.9017en
dc.identifier.urihttp://hdl.handle.net/10541/626656
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9017en
dc.titleIntracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMassachusetts General Hospital Cancer Center, Boston, MAen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record